|
|||||
|
|
Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma |
|
| Authors: | Junnan Kang Yizhuo Zhang Sa Ding Kalbinur Yasheng Yueyang Li Yong Yu Yafei Wang Chen Tian |
| Affiliation: | 1. Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China Contribution: Formal analysis (lead), Writing - original draft (lead);2. Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China Contribution: Investigation (equal), Supervision (equal), Validation (equal);3. Department of Oncology, Hetian District People's Hospital, Hotan, China Contribution: Writing - original draft (equal);4. Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China Contribution: Writing - original draft (equal);5. Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China Contribution: Writing - review & editing (equal);6. Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China |
| Abstract: | Triple-hit lymphoma (THL), which is classified into high-grade B-cell lymphoma with rearrangements of MYC, BCL2 and BCL6, presents aggressive biological behaviour. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is considered to be one of the recommended treatment options. Here, we reported 3 THL patients received carmustine, etoposide, cytarabine and cyclophosphamide (BEAC) combined with chidamide and high-dose rituximab conditioning regimen and found that this conditioning showed good efficacy and tolerance without increase of adverse events. |
| Keywords: | chidamide conditioning regimen high dose rituximab triple-hit lymphoma |